New Triple-Drug malaria treatment put to the test in major african trial

NCT ID NCT03923725

Summary

This large study tested whether adding a third anti-malaria drug to the standard two-drug combination is as effective or better at treating uncomplicated malaria in children. Over 2,500 children across Africa participated, receiving either the standard treatment or the new triple therapy. The goal was to see if the triple-drug approach could better control the infection and prevent it from coming back.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLASMODIUM FALCIPARUM MALARIA (UNCOMPLICATED) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah

    Conakry, B.P. 2649, Guinea

  • Centre for Malaria and Other Tropical Diseases (CEMTROD)

    Ilorin, Kwara State, 1459, Nigeria

  • College of Medicine and Health Sciences, University of Rwanda

    Kigali, Rwanda

  • Epicentre Niger

    Niamey, BP: 13 330, Niger

  • Institut des Sciences et Techniques (INSTech)

    Bobo-Dioulasso, Burkina Faso

  • Kinshasa School of Public Health

    Kinshasa, BP 11850 Kin, Democratic Republic of the Congo

  • MRC Unit The Gambia at LSHTM

    Fajara, City of Banjul, 273, The Gambia

  • National Institute For Medical Research (NIMR), Tanga Medical Research Centre

    Tanga, Tanzania

Conditions

Explore the condition pages connected to this study.